On Apr. 27, 2020, Atossa Therapeutics announced that it had contracted with NYC Health + Hospitals/Metropolitan in New York City to conduct the NY HOPE Study of Atossa’s proprietary combination drug therapy called AT-H201.

The NY HOPE Study evaluated AT-H201 in COVID-19 patients on ventilators with the goal of reducing the amount of time on ventilators.